Status:
UNKNOWN
Bacteriotherapy in the Treatment of COVID-19
Lead Sponsor:
University of Roma La Sapienza
Conditions:
COVID
Pneumonia
Eligibility:
All Genders
18+ years
Brief Summary
In light of its high morbidity and mortality, COronaVIrus Disease 19 (COVID-19) pandemic spread is considered an unprecedented global health challenge. Given the very limited therapeutic options avai...
Detailed Description
Italy was the first European country hit by the severe outbreak of the SARS-CoV-2 epidemic emerged from China, with a high morbidity and associated mortality. Given the limited treatment options curr...
Eligibility Criteria
Inclusion
- COVID-19 diagnosis
- symptomatic COVID-19
- hospitalization in infectious diseases wards
Exclusion
- Pregnant
- hospitalization in Intensive Care Unit
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2020
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04368351
Start Date
March 1 2020
End Date
July 31 2020
Last Update
May 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Public Heath and Infectious Diseases. University of Rome "Sapienza" (Italy)
Rome, Italy, 00161